Welcome to our dedicated page for Dermata Therapeutics SEC filings (Ticker: DRMA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Dermata Therapeutics, Inc. (DRMA) SEC filings page on Stock Titan aggregates the company’s official U.S. regulatory disclosures, offering a structured view of how this dermatology-focused biotechnology issuer reports its activities. Dermata uses SEC filings to describe progress with its Spongilla technology platform, clinical programs such as XYNGARI™ and DMT410, financing arrangements, and key corporate decisions.
Current and prospective investors can review Form 8-K filings for material events, including press release disclosures about clinical trial data, strategic pivots, financing transactions, and significant agreements. For example, Dermata has filed 8-Ks discussing its corporate updates and financial results, the presentation of Phase 3 STAR-1 acne data, increases to its at-the-market offering capacity, and the termination of a License Agreement with Villani, Inc. related to sponge-based pharmaceutical products.
Annual Form 10-K and quarterly Form 10-Q reports (when available) provide more comprehensive information on Dermata’s business, risk factors, financial statements, and details on its lead programs XYNGARI™ and DMT410. These filings also reference key licensing arrangements, intellectual property, and the company’s shift toward over-the-counter pharmaceutical dermatology products.
On Stock Titan, Dermata’s filings are complemented by AI-powered summaries designed to clarify complex sections of lengthy documents, such as clinical trial descriptions, capital structure changes, and agreement terms. Users can quickly understand the implications of new 8-Ks, 10-Qs, and 10-Ks without reading every page, while still having direct access to the full text filed with the SEC. This page also surfaces information relevant to equity offerings and at-the-market programs, helping readers follow how Dermata funds its dermatology pipeline and OTC initiatives.
Dermata Therapeutics major shareholder Gerald T. Proehl filed Amendment No. 8 to his Schedule 13D reporting updated ownership and recent transactions in Dermata Therapeutics, Inc. common stock. He may be deemed to beneficially own 694,530 shares of common stock, representing 24.7% of the outstanding shares, based on 2,809,753 shares outstanding as of January 7, 2026. This includes 24 shares and options for 1,669 shares held directly, 79,950 shares held by Proehl Investment Ventures LLC, and 612,828 shares held by certain trusts for which he is trustee.
Proehl Investment Ventures LLC separately reports beneficial ownership of 79,950 shares, or 2.8% of the common stock, and is no longer a beneficial owner of more than 5% as of December 23, 2025. The filing describes a December 23, 2025 private placement in which the issuer agreed to sell 1,484,312 shares, pre-funded warrants for up to 537,750 shares, and Series C and Series D warrants for up to 2,022,062 shares each at purchase prices of $2.04 per share and $2.039 per pre-funded warrant.
Through certain trusts, Proehl purchased 612,745 shares and warrants exercisable for 1,225,490 shares in the private placement, subject to beneficial ownership limits of 4.99% or, at the holder’s election, 9.99%. He also received an option for 37,500 shares on January 2, 2026 in his role as Chief Executive Officer, which is not yet counted as beneficially owned.
Dermata Therapeutics director David F. Hale reported a new stock option grant. On 01/02/2026, he was awarded a stock option to buy 2,500 shares of Dermata Therapeutics, Inc. common stock at an exercise price of $2.18 per share.
The option vests in twelve substantially equal monthly installments, with the first installment vesting one month after the grant date, as long as he remains in continuous service through each vesting date. Following this grant, he beneficially owns 2,500 derivative securities directly.
Dermata Therapeutics, Inc. director Kathleen D. Scott reported receiving a grant of stock options. The award covers 2,500 Stock Options (Right to Buy) Dermata common shares at an exercise price of $2.18 per share, with no cash paid at grant. These options were granted on 01/02/2026 and are held directly.
The options will vest in twelve equal monthly installments, with the first installment vesting one month after the grant date and additional portions vesting monthly thereafter, as long as Scott continues to serve the company through each vesting date. The options are scheduled to expire on 01/01/2036, and the filing shows 2,500 derivative securities beneficially owned following this transaction.
Dermata Therapeutics director Andrew Seth Sandler received a grant of stock options for 2,500 shares on January 2, 2026. The options have an exercise price of $2.18 per share and expire on January 1, 2036. They vest in twelve substantially equal monthly installments, starting one month after the grant date, contingent on his continuous service. Following this award, he beneficially owned 2,500 derivative securities directly.
Dermata Therapeutics executive Christopher J. Nardo, Senior VP and Chief Development Officer, reported a new equity award in the form of stock options. On January 2, 2026, he was granted an option to purchase 18,000 shares of Dermata Therapeutics common stock at an exercise price of $2.18 per share. The filing states that 25% of the shares underlying the option will vest on the 12‑month anniversary of the grant date, with the remaining 75% vesting in 36 equal monthly installments starting on that same 12‑month anniversary. Following this grant, he beneficially owns stock options for 18,000 shares, held as direct ownership.
Dermata Therapeutics director Brittany Bradrick reported a new equity award. On January 2, 2026, she was granted a stock option to buy 2,500 shares of common stock at $2.18 per share. The option was received at no cost and is held directly. Following this grant, she beneficially owns 2,500 derivative securities in the form of this option.
According to the vesting terms, the 2,500 underlying shares vest in twelve substantially equal monthly installments. The first installment vests on the one‑month anniversary of the grant date, with additional installments vesting monthly thereafter, as long as she continues in service through each vesting date.
Dermata Therapeutics, Inc. has filed a replacement shelf registration statement allowing it to offer up to $100,000,000 of common stock, preferred stock, warrants, debt securities, subscription rights and units from time to time. This base shelf, filed under Rule 415(a)(6), refreshes unsold securities from a prior registration and preserves the company’s ability to raise capital as needed. As of November 21, 2025, Dermata had 1,026,457 shares of common stock outstanding and a public float of 910,575 shares valued at $2,258,226 based on a $2.48 share price. The company is pivoting from prescription dermatology to over-the-counter, science-backed skin-care products built on its Spongilla technology, targeting acne and other common skin conditions, with an initial once-weekly topical acne kit expected to launch in mid‑2026. Dermata remains pre‑revenue, reported net losses of $5.7 million for the nine months ended September 30, 2025, and plans to use any proceeds primarily for working capital and general corporate purposes.
Dermata Therapeutics, Inc. announced that it has elected to terminate its License Agreement with Villani, Inc., with the termination becoming effective 90 days after Villani receives the notice. This move is tied to Dermata’s recent strategic shift toward commercializing over-the-counter skin care treatments and its withdrawal of the XYNGARI™ investigational new drug application with the U.S. Food and Drug Administration.
Under the original agreement, Villani had granted Dermata an exclusive, sub-licensable, royalty-bearing license to develop and sell sponge-based pharmaceutical products for skin diseases and conditions. Dermata had agreed to pay up to $40.5 million in future development and sales milestone payments, plus single-digit royalties on net sales. After the termination date, Villani will not receive further milestone or other payments, Dermata’s development and commercialization obligations for licensed products will end, and the Villani licenses will cease to be in effect.
Dermata Therapeutics (DRMA) filed its Q3 2025 report, showing lower losses and a strategic pivot to over-the-counter (OTC) dermatology products. Net loss was $1.69 million for the quarter, improving from $3.17 million a year ago, as research and development fell to $0.50 million with its Phase 3 STAR-1 trial completed. Selling, general and administrative expense rose to $1.26 million, including $0.33 million of related party amounts tied to branding and launch preparation.
Cash and cash equivalents were $4.66 million as of September 30, 2025, with total liabilities of $1.11 million and stockholders’ equity of $3.96 million. The company expects its cash to fund operations into the second quarter of 2026 and disclosed substantial doubt about its ability to continue as a going concern. Management plans to launch its first OTC product candidate in mid-2026. Capital raised year-to-date included approximately $5.7 million from a March 2025 warrant inducement and approximately $2.2 million net from a January 2025 PIPE. A 1‑for‑10 reverse stock split became effective August 1, 2025. Shares outstanding were 1,026,457 as of November 12, 2025.
Dermata Therapeutics, Inc. furnished an 8-K announcing a press release with a corporate update and financial results for the quarter ended September 30, 2025. The press release is attached as Exhibit 99.1, titled “Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results.”
The information under Item 2.02 and Exhibit 99.1 is furnished, not deemed filed under Section 18 of the Exchange Act, and is not incorporated by reference unless expressly stated.